PROGRAMM JAHRESTAGUNG 2012 30. Nov. – 2. Dez ... - ÖGDV

Poster Infektionen der Haut
P 27
Identification of HPV vaccine-genotypes in a female STI population group
Natalie Isabella Hartl 1
Claudia Heller-Vitouch 1
Angelika Stary 1
1 Outpatients Centre for STD Diagnosis, Vienna, Austria
Background and Objectives: Women harbouring HPV genotypes are at risk to develop
either genital warts or cervical dysplasia as a precursor of cervical carcinoma. Aim of
the study was to evaluate the prevalence of HPV vaccine-genotypes in a symptomatic
and asympytomatic female population group. Furthermore, an age-related distribution
of different genotypes was investigated for different clinical syndromes.
Materials and Methods: Data were collected from 4230 patients between February
and July 2012. Material was either delivered or sent to the Outpatients Centre laboratory
or sampled and processed at the Outpatients Centre. Clinical diagnosis was assessed
by the referring physician. Samples were collected either from the cervical area or from
genital lesions by Cytobrush DNAPAP Cervical Sampler. Viral DNA detection and HPV
genotyping was performed using Papillo Check PCR. Data from women with the diagnosis
of cervical dysplasia and cervical cancer precursors including PAP III, IIID, IV and
CIN I, II, III (n= 1485) and genital warts, respectively, were included. Additionally, data
were evaluated according to age groups of women from 20 to 30 and 50 to 60 years.
Results: Out of all 1485 patients with cervical dysplasia and cervical cancer precursors
55,2% were HPV high-risk positive. In 29.5% infection with HPV 16, and in 6.1%, respectively,
HPV 18 could be detected. Furthermore, referring to vaccination cross immunity
HPV 31, 33, 45, and 52 were detected in 14,9% 7,7% , 2,9% and 6,2% respectively. When
focusing on the younger age group, 32.9% of all high risk positive patients with cervical
dysplasia and cervical cancer precursors turned out to be positive for HPV 16, and 7.8%
for HPV 18. Other frequently detected HPV high-risk types in this age group were HPV
31 (14%), HPV 45 (1,9%), HPV 51 (19,2%) and HPV 56 (9,3%). In contrast to these results,
in women between 50 and 60 years of age with cervical dysplasia and cervical cancer
precursors an infection with HPV 16 was detected only in 20%, with HPV 18 in 4% and
with HPV 45 in 6%, respectively. In addition, HPV 51 was detected in 12% and HPV 56
in 18%. The identification of genotypes evaluated for different age groups shows that
both strains, HPV 16 and 18, were more often detected in young women and decreased
with increasing age. In contrast, an increase of HPV high-risk types other than 16 and
18, such as HPV 45 and 56, were more often identified in older women. In the group of
individuals with genital warts (n=558), HPV-low-risk types were detected in 42.8%. The
genotyping showed a higher detection rate of HPV 6 (60,7%) compared with HPV 11 (10.5%).
Conclusion: A high number of the HPV high-risk types 16 and 18 was detected
especially in the group of young women compared with women in the higher age
74